Sun Pharma Announces $11.75 Bn All-Cash Acquisition of Organon

Under the definitive agreement, Sun Pharma will acquire all outstanding Organon shares for $14 per share, representing a significant strategic expansion for India’s largest revenue-generating pharmaceutical company.

Sun Pharmaceutical Industries Limited has agreed to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, one of the largest outbound transactions by an Indian drugmaker, the companies said on April 27, 2026.

Under the definitive agreement, Sun Pharma will acquire all outstanding Organon shares for $14 per share, representing a significant strategic expansion for India’s largest revenue-generating pharmaceutical company.

The deal, which has been approved by the boards of both companies, is expected to close in early 2027, pending regulatory approvals and shareholder consent.

Dilip Shanghvi, Executive Chairman of Sun Pharma, said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform."

Organon was removed from Merck & Co. in 2021 and has operations in women’s health and established brands. It has more than 70 products available across 140 countries, with a presence in markets including the US, Europe, China, Canada, and Brazil, and six manufacturing facilities in the European Union and emerging markets.

Kirti Ganorkar, Managing Director of Sun Pharma, said, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration, and responsible value creation."

After the acquisition, the combined company is expected to generate revenues of about $12.4 billion, placing it among the top 25 pharmaceutical companies globally. The deal is also expected to strengthen Sun Pharma’s position in women’s health, where it would rank among the top three global players, while extending its presence to 150 countries.

Carrie Cox, Executive Chair of Organon, commented, “We believe Sun Pharma is well positioned to support Organon’s businesses, employees, and patients globally and to further advance our commitment to delivering impactful medicines and solutions.”

Stay tuned for more such updates on Digital Health News